The role of bimatoprost eyelash gel in chemotherapy-induced madarosis: An analysis of efficacy and safety

International Journal of Trichology

Volumn 3, Issue 2, 2011, Pages 84-91

  Morris, Carrie L ^a,b   Stinnett, S S ^a   Woodward, J A ^a  

^a UNIVERSITY OF NORTH FLORIDA   (United States)

^b Brevard Eye Center   (United States)

Author keywords

Bimatoprost; chemotherapy; eyelash; hypotrichosis; madarosis

Indexed keywords

EID: 84865597265     PISSN: 09747753     EISSN: 09749241     Source Type: Journal    
DOI: 10.4103/0974-7753.90809     Document Type: Article

References (17)

1. Tosti A, Pazzaglia M, Voudouris S. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol 2004: S149-50.
2. Namazi MR. Prostaglandin analogs for hair growth: Greater expectations. Dermatol Online J 2003;9:29.
3. Galloway GD, Eke T, Broadway DC. Periocular Cutaneous Pigmentary Changes Associated with Bimatoprost Use. Arch Ophthalmol 2005;123:1609-10.
4. Kapur R. Bimatoprost-induced periocular skin pigmentation. Arch Ophthalmol 2005;123:1541-6.
5. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmoly 2002;47: S185-201.
6. Wolf R, Matz H, Zalish M, Pollack A, Orion E. Prostaglandin analogs for hair growth: Great expectations. Dermatol Online J 2003;9:1-7.
7. Mansberger S, Coiffi G. Eyelash formation secondary to latanaprost treatment in a patient with alopecia. Arch Ophthalmol 2000;118:718-9.
8. Kawano M, Komi-Kuramochi A, Asada M, Suzuki M, Oki J, Jiang J, et al. Comprehensive analysis of FGF and FGFR expression in skin: FGF18 is highly expressed in hair follicles and capable of inducing anagen from telogen stage hair follicles. J Invest Dermatol 2005;124:877-85.
9. Saski S, Hozumi Y, Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol 2005;14:323-8.
10. Tran D, Sinclair RD, Schwarer AP, Chow C W. Permanent alopecia following chemotherapy and bone marrow transplantation. Australas J Dermatol 2000;41:106-8.
11. Age Intervention Eyelash. Available from: www.fda.gov/safety/medwatch/ safetyinformation. [Last cited on 2007 Nov 11].
12. Hart J, Shafranov G. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol 2004;137:756-7.
13. Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: Changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009;25:145-52.
14. Pathanapitoon K, Kunavisarut P. Choroidal detachment after topical prostaglandin analogs: Case report. J Med Assoc Thai 2005;88:1134-6.
15. Noecker R, Bulau S, Schwiegerling J. Xalatan-induced changes in periocular skin pigmentation and lash dimensions measured using a digital imaging technique. Invest Ophthalmol 1999;40: S832.
16. Hart J, Sharanov G. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol 2004;137:756-7.
17. Centofani M, Oddone F, Chimenti S, Tanga L, Citarella L, Manni G. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Am J Ophthalmol 2006;142:1059-60.